PubMed Health⌕ Search

Biomedical subjects

L Bette

Publications and source records attributed to L Bette.

At least 19 recordsLinked to original sources
PubMed1990

Modern strategies for treatment of acute myocardial infarction: significance of haemostaseological and rheological findings.

In spite of equivalent clinical efficacy of various thrombolytic agents for the treatment of acute myocardial infarction there is evidence of different drug-depending influences on the haemostatic and fibrinolytic system. In the present study 40 patients with acute myocardial infarction have been investigated. 20 patients received 750,000 and 1.5 mio U streptokinase (SK), respectively, 10 patients 30 mg anisoylated plasminogen streptokinase activator complex (BRL 26921) and 10 patients a combination of 200,000 U urokinase (UK) and 4.5 mio U pro-urokinase (PUK) as a short-term intravenous treatment. Reperfusion of coronary arteries has been achieved in 70 to 100 percent. Major not fatal bleedings occurred in 2 patients. One patient died within 72 hours after beginning of the myocardial infarction. The longest duration of fibrinolytic activity was observed in the BRL 26921 group (half-disappearance time close to 2 h). It was significantly shorter in the SK groups showing a dose-dependency. Plasma concentration of fibrinogen dropped beyond normal levels following SK and BRL 26921, but not under UK/PUK. Plasma viscosity correlated with fibrinogen decrease and displayed a dose-depending relationship with the presence of SK. Haemorheological effects are suggested to be important for the clinical efficacy of thrombolytic therapy in myocardial infarction.

Anistreplase↗
PubMed1990

[Coincidence of hypertensive fundus changes and regulatory disorders of peripheral microcirculation. II--Skeletal muscles].

In patients with hypertensive fundus changes considerable morphologic changes of the entire vascular system may be assumed. In the present study, the effects of these processes on the partial oxygen pressure of the skeletal musculature were investigated in 62 patients via a macro puncture electrode placed in the tibial muscle. The extent of fundus changes and the reduction in muscular partial oxygen pressure were found to be correlated. With advancing stages of fundus changes, blood flow measured in the common carotid artery decreased. Vascular changes which are clearly recognizable in the hypertensive fundus thus appear to be accompanied by a deterioration in partial oxygen pressure in muscular tissue and restriction of flow in the macrocirculation.

Aged↗
PubMed1990

Optimised function for determining time to peak creatine kinase and creatine kinase-MB as non-invasive reperfusion indicators after thrombolytic therapy in acute myocardial infarction.

STUDY OBJECTIVE: The aim of the study was to investigate the use of an optimised function to approximate and interpolate the time course of serum creatine kinase and creatine kinase-MB values after thrombolytic therapy in acute myocardial infarction. DESIGN: A three parameter interpolating function was developed which approximates the time course of serum enzyme levels. In the proposed function, time to peak creatine kinase and maximum of creatine kinase determined from raw data were used as starting parameters of the non-linear interpolation routine, thus providing ideal starting conditions for the iteration. The efficacy of the function was compared with that of three other functions cited in published reports (log-normal distribution function, modified gamma density function, three compartment function). SUBJECTS: Serum enzyme data from 20 patients with acute myocardial infarction were used in the comparisons. The patients have all been treated with anisoylated plasminogen streptokinase activator complex. RESULTS: In comparison with the other models, deviations of the experimental model function from the raw data were minimal. The fit remained stable for time intervals between blood samples of up to 6 h. CONCLUSIONS - Due to its numerical stability, the function outlined in this study is suitable for large clinical reperfusion trials. In the case of uncomplicated infarctions without thrombolytic therapy, the area under the creatine kinase activity curve could be directly calculated in terms of maximum activity and time to peak.

Anistreplase↗
PubMed1989

Effects of fish oil capsules in two dosages on blood pressure, platelet functions, haemorheological and clinical chemistry parameters in apparently healthy subjects.

The effects of a fish oil concentrate with an omega-3 fatty acid content of 42% was determined in two dosages in a double-blind, placebo-controlled study with a parallel group comparison over a period of 5 weeks with 30 healthy subjects. The daily intake chosen was four and eight capsules corresponding to 1.26 or 2.52 g omega-3 fatty acids. Plasma viscosity, erythrocyte rigidity and systolic blood pressure were significantly decreased (p less than 0.01) after a 5-week administration of 2.52 g omega-3 fatty acid daily. The reduction in vitamin E concentration was significant (p less than 0.01) only in the low-dose fish oil group. Lipids and lipoproteins remained unchanged throughout this experiment.

Adult↗
PubMed1988

Antianginal efficacy of gallopamil in comparison to nifedipine.

In a randomized double-blind crossover trial 30 patients with chronic stable angina were studied to compare the antianginal actions of gallopamil (150 mg/day) and nifedipine. With the initial nifedipine dose of 60 mg/day, the trial had to be stopped because of severe exacerbation of angina in 3 patients of the nifedipine group. Twenty-one patients were entered into a second protocol with the nifedipine dose reduced to 30 mg/day. Compared to the preceding placebo period, the exercise time to onset of angina (+ 30%, P less than 0.01) and the total exercise time (+ 18%, P less than 0.01) were prolonged by gallopamil but not by nifedipine (+ 20 and 13%, respectively, not significant) with no significant difference between the test drugs. Four patients became free of angina during exercise testing with gallopamil therapy and one patient with nifedipine. Both agents significantly reduced ST depression at maximal comparable workload by 77% (gallopamil) and 52% (nifedipine) compared with placebo; the difference between the drugs reached borderline significance (P = 0.055). The increase in heart rate and the rate-pressure product at maximal comparable workload was less with gallopamil than with nifedipine (P less than 0.01). In contrast to nifedipine, very few side effects were reported with gallopamil. Thus, gallopamil is an effective antianginal agent whose therapeutic to toxic ratio appears to be superior to that of nifedipine.

Adult↗
PubMed1988

Atrial signal variations and pacemaker malsensing during exercise: a study in the time and frequency domain.

To give some explanation for atrial malsensing in dual chamber pacing that occurs only during exercise, atrial electrograms from 33 patients were telemetrically recorded and analyzed in both the time and frequency domains. During exercise, an overall decrease from 6.4 +/- 1.9 to 5.6 +/- 1.9 mV (-11%) in the atrial signal amplitude was noted. Despite considerable variability among patients, marked changes occurred in 15 patients whose signals diminished by 11 to 49%. Slew rates showed a similar decrease from 1.35 +/- 0.45 to 1.18 +/- 0.45 V/s (-10.8%), with individual changes of as much as -51%. Signal attenuation in the time domain correlated well with frequency data, exhibiting a highly significant reduction of signal energy between 25 and 105 Hz. However, spectral distribution changed from rest to exercise, with a relative increase of signal energy in the range between 5 and 25 Hz and a decrease at higher frequencies. Individual changes differed widely when low (15 to 65 Hz) and high (65 to 115 Hz) frequencies were compared, but in a group of 11 patients signal attenuation in the high frequency band was more pronounced (-45%) than in the low frequency band (-23%). The clinical impact of the change in frequency distribution during ergometry was visualized by computer simulation of two different (low and high bandpass) filters. Although in individual patients, both characteristics may be favorable with respect to atrial sensing, it was observed in 11 patients that high pass filtering attenuates signal amplitudes by 10 to 24% in excess of the variation without filtering.(ABSTRACT TRUNCATED AT 250 WORDS)

Adolescent↗
PubMed1988

Atrial sensing performance of AV universal pacemakers during exercise.

To investigate the atrial sensing function of dual chamber pacemakers during exercise, we studied 57 patients aged 12 to 81 years (m = 65). They were paced for sinoatrial disorders (n = 15), second or third degree AV block (n = 37), or binodal disease (n = 11). The examination was performed 3-24 months (m = 11) after pacemaker implantation. Individual sensing thresholds were determined at rest in the supine position, and proper detection of atrial signals at the programmed sensitivity level was verified during a period of 5-9 minutes (m = 5.8). Without a change in the program of the unit, symptom-limited bicycle ergometry was performed at a maximum load of 25-200 Watts (m = 95) and 6-channel chest wall electrocardiograms were continuously recorded throughout the test, including recovery. During exercise, 25/57 patients (44%) exhibited poor atrial sensing of the pulse generator; after termination of exercise in 16 of the 25 patients, proper atrial sensing resumed within 1 to 7 minutes of recovery. In the remaining nine cases, ergometry was continued after lowering the sensitivity threshold to half the initial setting or, depending on the pacemaker model, by a value of 0.4 mV. This resulted in normal function of the pulse generator in all patients but one, who needed a sensitivity adjustment of another 0.4 mV. In a subgroup of 25 patients, telemetric atrial electrogram recordings were monitored during ergometry, 19 of which could be evaluated quantitatively. Besides random atrial signal variations, presumably due to ectopic beats or runs, a systematic decrease of the peak-to-peak amplitude by 0.1 to 1.6 mV (3-30%) was observed in 16/19 patients during exercise. Mean signal reduction amounted to 11.8% and was statistically significant at the 0.1% level. It is concluded from these findings that, besides testing of atrial sensing at rest, the follow-up of dual chamber pacemakers should include an exercise test.

Adolescent↗
PubMed1988

Correlation of cardiac arrhythmias with brainstem compression in patients with intracerebral hemorrhage.

Neurogenically caused cardiac arrhythmias and their correlation to lesions within the central nervous system were examined prospectively in 54 patients with spontaneous intracerebral hemorrhage. All patients were examined neurologically daily for 3 weeks, with special attention given to signs of brainstem compression resulting from transtentorial herniation. Electrocardiograms were continuously recorded over an average of 5 days. A significant correlation was established between the clinical manifestations of brainstem compression and sinus arrhythmias, multifocal premature ventricular contractions, couplets, and ventricular tachycardias. An explanation for this correlation may be found in the localization of the autonomous cardiovascular centers in the hypothalamus and brainstem. Transtentorial herniation frequently leads to a bilateral lesion of these structures. However, the cardiac arrhythmias are only a partial phenomenon within a complex cardiovascular reaction.

Adult↗
PubMed1988

Current therapy of acute heart failure.

Acute heart failure involves various pathophysiological mechanisms among which primary reduction of myocardial contractility due to acute myocardial infarction, cardiomyopathy, and after open heart surgery are the most common. Therapy should be as causally related as possible. In patients with mechanical defects such as rupture of the interventricular septum or acute mitral regurgitation due to papillary muscle rupture, surgical correction is mandatory. Systemic hemodynamics can often be temporarily stabilized by mechanical circulatory assist devices until spontaneous recovery has occurred or definitive treatment is possible. The objectives of medical therapy are to relieve pulmonary congestion and to provide adequate systemic tissue perfusion. This is achieved by carefully balancing and monitoring a selection of pharmacological approaches according to each patient's hemodynamic profile. Ventricular filling pressure may be reduced by potent loop diuretics and venous dilating drugs with preservation of an optimal pressure range of 15-18 mmHg; cardiac output can be increased by afterload reduction and/or positive inotropic drugs; preservation of systemic perfusion pressure may necessitate use of arteriolar constrictor therapy. Most of these hemodynamic objectives are met by agents with combined vasodilatory and inotropic effects, e.g., dobutamine and amrinone. Whilst both agents are equally effective at improving pump performance, amrinone, unlike dobutamine, has the advantage of doing so without increasing myocardial oxygen consumption and without tolerance development or significant arrhythmogenicity.

Acute Disease↗
PubMed1988

[Isovolemic hemodilution in patients with coronary heart disease].

In the age of cellsavers patients suffering from coronary heart disease are diluted to a hematocrit of 20% or even less during a surgical intervention in the coronaries and they leave the operating room with a hematocrit of 30%. On the other hand, a hemodilution to a level of 30% in patients with coronary heart disease represents a contraindication due to the limited coronary reserve. On the occasion of the collection of autologue blood, before vascular surgery or for therapeutical hemodilution, the hematocrit was reduced from 45 to 35% by means of an isovolemic hemodilution with 500 ml of Haes 200/0.5 10% in 50 patients. In the load-ECG the pressure X frequency-product and the dyspnoe decreased significantly. The microcirculation in the nailfold and the systemical blood fluidity increased significantly. As in 22% of the patients a deterioration was stated, we propose to dilute all the patients who have to undergo a coronary vessel operation without exclusion criteria once isovolemically and to stress them before and afterwards. The patients having a clinical defict should be diluted intraoperatively only to 30% and postoperatively not under 35%.

Angina Pectoris↗
PubMed1988

[Dose-related effect of nicainoprol (CAS 924) on basic electrophysiologic parameters in patients with and without diseases of the heart conduction system].

The dose-dependent effects of nicainoprol (1 and 2 mg/kg/h), a new antiarrhythmic drug, on invasive electrophysiological parameters were evaluated in 28 patients during diagnostic electrophysiologic studies. The most pronounced effects by nicainoprol were observed on the specialized AV conduction system. The intranodal (1 mg/kg/h: A-H interval: 92 +/- 19 ms to 107 +/- 25 ms, p less than 0.002, n = 13; 2 mg/kg/h: 92 +/- 18 ms to 114 +/- 27 ms, p less than 0.001, n = 16) and, in particular, the infranodal conduction time (1 mg/kg/h: H-V interval: 45 +/- 5 ms to 52 +/- 9 ms, p less than 0.001, n = 15; 2 mg/kg/h: 45 +/- 6 ms to 58 +/- 10 ms, p less than 0.0001, n = 18) were delayed in a dose-dependent fashion. With the higher dose, there was a highly significant prolongation of the AV nodal Wenckebach cycle length (380 +/- 69 ms to 440 +/- 79 ms, p less than 0.0001, n = 13) as well as of the effective (368 +/- 112 ms to 428 +/- 108 ms, p less than 0.001, n = 12) and functional refractory periods (470 +/- 102 ms to 521 +/- 135 ms, p less than 0.001, n = 15). The intraatrial conduction time was slightly prolonged for both doses, the intraventricular conduction time increased significantly with the higher dose (89 +/- 12 ms to 102 +/- 19 ms, p less than 0.001, n = 19). In contrast, there were only small changes of right atrial and right ventricular refractorion.(ABSTRACT TRUNCATED AT 250 WORDS)

Anti-Arrhythmia Agents↗
PubMed1987

High-dose systemic streptokinase and acylated streptokinase-plasminogen complex (BRL 26921) in acute myocardial infarction: alterations of the fibrinolytic system and clearance of fibrinolytic activity.

We report the results of two consecutive studies using intravenous bolus injections of streptokinase (SK) or acylated plasminogen-SK complex (BRL 26921) in patients with acute myocardial infarction (AMI). In the first study, 20 patients received either 750,000 units (U) SK (group IA, n = 10) or 1,500,000 U SK (group IB, n = 10) within 5-10 min intravenously. In the second study 10 consecutive patients received 750,000 U SK within 15 min (group IIA) intravenously. The following 10 consecutive patients received 30 mg BRL 26921 within 2 min (group IIB). Early reperfusion was found in 16 patients in the first study (8 in each group) and in 18 patients in the second study (9 in each group). The decrease of fibrinolytic activity was biphasic with a half-disappearance time of 112.5 min for BRL 26921 and 31 (IA) and 18 (IB) min for SK. alpha 2-Antiplasmin depletion and a decrease of fibrinogen was observed with no differences after bolus injections of SK and of BRL 26921.

Aged↗
PubMed1986

[Bolus injection of anisoylated plasminogen-streptokinase activator complex (BRL 26921) as an alternative concept of systemic lysis in acute myocardial infarct].

The thrombolytic properties of anisoylated plasminogen streptokinase activator complex (BRL 26921) and clinical results of the treatment were studied in 10 consecutive patients with acute myocardial infarction. Exclusion criteria were general contraindications against thrombolytic therapy and a time interval of more than 4 h between the onset of symptoms and admission to the hospital. All patients received a 250-mg bolus of prednisolone prior to intravenous injection of 30 mg BRL 26921 within 2 min. A continuous infusion of heparin at a dose of 1,000 USPU/h was started 2 h after the injection. Blood pressure was monitored via an arterial line. Arrhythmias and changes in the ST segments were documented by conventional ECG recording and computer-based ECG monitoring. Coronary arteriography and left ventriculography were carried out within 72 h. Besides routine laboratory tests, serial CK and CK-MB activity measurements were carried out. We determined the following hemostaseological parameters before and 15 min, 30 min, 1 h, 4 h, and 12 h after application of BRL 26921: prothrombin time, activated partial thrombosplastin time, thrombin time, thrombin coagulase time, fibrinogen, streptokinaseplasminogen activator activity, plasminogen and alpha-2-antiplasmin. Our results (reperfusion in all patients angiographically and in 7 to 8 of 10 patients from noninvasive criteria) show that BRL 26921 is a highly effective thrombolytic agent in patients with myocardial infarction, when compared with high-dose systemic fibrinolysis. Applied in dosages required for early reperfusion, it does not appear to be selectively thrombolytic and is not free of hypotensive effects in man. The decrease of fibrinolytic activity is biphasic with a half-disappearance time of 112 min.

Adult↗
PubMed1986

Withdrawal of long-term amrinone therapy in patients with congestive heart failure: a placebo controlled trial.

To verify favourable long-term effects, 14 patients with chronic congestive heart failure, NYHA class II-IV, who had been treated with oral amrinone for 8-15 months with apparent clinical benefit, had the drug withdrawn according to a 12 week placebo controlled double-blind crossover protocol. Evaluation was performed noninvasively by means of exercise stress test, echocardiogram, radionuclide angiography and systolic time intervals. None of these variables were significantly changed after discontinuation of amrinone, regardless of whether placebo was introduced during the first (group B, N = 7) or the second 6 week period (group A, N = 5), nor when the medication was finally openly withheld for another 6 weeks. In 2 further group A patients, premature termination of the trial was due to deterioration of symptoms on blinded amrinone. Hence, no sustained drug related effects could be proven by controlled withdrawal of long-term amrinone in this trial.

Adult↗